Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer.
The recent study showed that HER2 overexpression or amplification is noted about 5-15% of
total biliary tract cancer patients and have shown efficacy in small basket trials. The aim
of this study is to evaluate the efficacy and safety of trastuzumab in the combination of
mFOLFOX for gemcitabine+cisplatin refractory biliary tract cancer patients.